Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
DNA-PK Inhibitor
SU-11752 is a potent inhibitor of DNA-dependent protein kinase (DNA-PK), exhibiting an IC50 value of 0.13 μM. This compound also inhibits the PI3K p110γ kinase with an IC50 of 1.1 μM. By competitively binding to the ATP-site of DNA-PK, SU-11752 effectively disrupts intracellular DNA double-strand break repair mechanisms, thereby enhancing the sensitivity of cells to radiotherapy. This makes it a valuable tool in cancer research and therapy applications. -
DNA-PK Inhibitor
DNA-PK-IN-3 is a selective inhibitor of DNA-dependent protein kinase (DNA-PK), an essential component of DNA repair mechanisms. This compound enhances the efficacy of radiotherapy and chemotherapy while effectively inhibiting tumor growth. Additionally, DNA-PK-IN-3 has been shown to minimize damage to normal cells, thereby reducing associated side effects. Its potential applications extend to cancer research, providing valuable insights into therapeutic strategies targeting DNA repair pathways. -
DNA-PK Inhibitor
DNA-PK-IN-1 is a potent inhibitor of DNA-dependent protein kinase (DNA-PK), a key enzyme complex comprised of the Ku70/Ku80 heterodimer and the DNA-PK catalytic subunit (DNA-PKcs). This compound exhibits significant activity in inhibiting DNA-PK, making it a valuable tool for investigating DNA damage response and repair mechanisms in cancer research. Its application is particularly relevant in studies aimed at understanding tumor biology and developing targeted cancer therapies. -
DNA-PK Inhibitor
ZL-2201 free base is a highly selective inhibitor of DNA-dependent protein kinase (DNA-PK), demonstrating an IC50 of 1 nM. This compound has significant implications in research applications focused on DNA repair mechanisms, cancer therapy, and radiation sensitization. ZL-2201 is ideal for studies investigating the modulation of DNA damage response pathways. -
DNA-PK inhibitor
DNA-PK-IN-14 is a potent selective inhibitor of DNA-dependent protein kinase (DNA-PK) with an IC50 value of 7.95 nM. This compound exhibits oral bioactivity and demonstrates potential as a radiosensitizer in cancer treatment. It can be utilized in research applications focusing on DNA repair mechanisms and the enhancement of radiotherapy efficacy. -
DNA-PK Inhibitor
DNA-PK-IN-4 is a potent inhibitor of DNA-dependent protein kinase (DNA-PK), specifically targeting DNA-PKcs activity. As an imidazolinone derivative, it effectively diminishes DNA repair capabilities in tumor cells, leading to increased apoptosis. This compound is valuable for research applications focused on cancer biology and the exploration of therapeutic strategies targeting DNA repair pathways. -
DNA-PK Inhibitor
DNA-PK-IN-10 is a selective inhibitor of DNA-dependent protein kinase (DNA-PK), a critical enzyme involved in the DNA damage response and repair mechanisms. This compound has demonstrated significant potential in the investigation of tumorigenesis, particularly in breast cancer and non-small cell lung cancer models. Its application in research may aid in understanding the roles of DNA-PK in cancer cell survival and resistance to therapies, providing insights for the development of targeted treatments. -
DNA-PKcs Inhibitor
IC-87361 is a selective inhibitor of DNA-dependent protein kinase catalytic subunit (DNA-PKcs), serving as a potent radiosensitizer. By inhibiting the catalytic activity of DNA-PKcs, IC-87361 effectively disrupts non-homologous end joining (NHEJ) pathways involved in the repair of DNA double-strand breaks. This compound is particularly valuable in research related to lung cancer and melanoma, providing insights into therapeutic strategies that target DNA repair mechanisms. -
DNA-PK Inhibitor
DNA-PK-IN-6 is a selective inhibitor of DNA-dependent protein kinase (DNA-PK), specifically targeting DNA-PKcs activity. By inhibiting this kinase, DNA-PK-IN-6 significantly reduces the DNA repair capacity of tumor cells, thereby promoting apoptosis. This compound enhances the sensitivity of various solid tumors and hematological malignancies to radiotherapy, addressing challenges related to treatment resistance. Its applications are crucial for research in cancer therapeutics and treatment strategies. -
DNA-PK Inhibitor
OK-1035 is a selective inhibitor of DNA-dependent protein kinase (DNA-PK), exhibiting an IC50 value of 100 μM. It interferes with DNA double strand break repair mechanisms, thus providing valuable insights into cellular responses to DNA damage. This compound has potential applications in cancer research, particularly in studies focused on enhancing the efficacy of radiotherapy and chemotherapeutics. -
DNA-PK Inhibitor
NU-7163 is an ATP-competitive inhibitor of DNA-dependent protein kinase (DNA-PK), demonstrating an IC50 of 0.19 μM and a Ki of 24 nM. This compound enhances the cytotoxic effects of ionizing radiation in the HeLa human tumor cell line, making it a valuable tool for research in cancer biology and therapeutic development. NU-7163 may be particularly relevant in studies exploring DNA repair mechanisms and enhancing the effectiveness of radiotherapy. -
eIF Inhibitor
GCN2-IN-6 is a selective inhibitor of GCN2, exhibiting potent activity with an IC50 of 1.8 nM in enzymatic assays and 9.3 nM in cellular contexts. Additionally, this compound acts as an eIF2α kinase PERK inhibitor, demonstrating an IC50 of 0.26 nM enzymatically and 230 nM in cellular assays. GCN2-IN-6 also features an alkyne functional group, allowing it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc), making it valuable for biochemical research applications. -
eIF4e Inhibitor
eIF4E-IN-2 is a potent inhibitor targeting eukaryotic initiation factor 4E (eIF4E), with an IC50 of 13 nM. This compound effectively inhibits the proliferation of MDA-MB-361 breast cancer cells, thereby demonstrating its potential in cancer research. eIF4E-IN-2 can be utilized for studies investigating the role of eIF4E in breast cancer progression and therapeutic interventions. -
eIF4A3 Inhibitor
eIF4A3-IN-8 is a selective ATP-competitive inhibitor targeting eukaryotic initiation factor 4A3 (eIF4A3). This compound functions as a valuable chemical probe for investigating the role of eIF4A3 in mRNA processing and the exon junction complex (EJC). Its ability to modulate eIF4A3 activity makes it a useful tool for research into gene expression regulation and related biological pathways. -
eIF4E/eIF4G Interaction Inhibitor
(Z)-4EGI-1 is an inhibitor of the interaction between eIF4E and eIF4G, targeting translation initiation. With an IC50 of 43.5 μM and a Kd value of 8.74 μM, (Z)-4EGI-1 demonstrates significant binding affinity for eIF4E. This compound exhibits anticancer activity, making it a valuable tool for research in cancer biology and studies focused on the regulation of protein synthesis. -
eIF4F Inhibitor
eIF4A3-IN-18 is an effective eIF4F inhibitor that disrupts the assembly of the eIF4F translation complex. It demonstrates potent biological activity with EC50 values of 0.8 nM for myc-LUC, 35 nM for tub-LUC, and inhibits growth in MBA-MB-231 cells. Additionally, eIF4A3-IN-18 exhibits significant cytotoxicity towards RMPI-8226 cells, with an LC50 of 0.06 nM. This compound is valuable for research into the mechanisms of human cancer pathogenesis. -
eIF4F Inhibitor
eIF4A3-IN-12 is an eIF4F inhibitor, specifically disrupting the assembly of the eIF4F translation complex. With EC50 values of 4 nM for myc-LUC, 70 nM for tub-LUC, and 5 nM for inhibiting the growth of MBA-MB-231 cells, this compound demonstrates potent biological activity. eIF4A3-IN-12 is valuable for investigating human cancer pathogenesis and understanding the role of translation regulation in tumorigenesis. -
eIF4F Inhibitor
eIF4A3-IN-16 is a potent eIF4F inhibitor that selectively disrupts the assembly of the eIF4F translation complex. It demonstrates significant biological activity, inhibiting MBA-MB-231 cell growth with an EC50 of 1 nM. Additionally, eIF4A3-IN-16 affects myc-LUC and tub-LUC with EC50 values of 1 nM and 30 nM, respectively. This compound is applicable in research focused on triple negative breast cancer (TNBC). -
eIF4e Inhibitor
eIF4E-IN-3 is a highly effective inhibitor of eukaryotic initiation factor 4E (eIF4E), a critical component in the protein synthesis initiation pathway. This compound demonstrates significant potential in investigating eIF4E-dependent diseases, particularly in cancer research. By modulating eIF4E activity, eIF4E-IN-3 offers valuable insights into the molecular mechanisms underlying tumorigenesis and may aid in the development of targeted therapeutic strategies. -
eIF4F Inhibitor
eIF4A3-IN-15 is a targeted inhibitor of the eIF4F translation complex, effectively disrupting its assembly. This compound demonstrates potent activity with EC50 values of 11, 700, and 120 nM against myc-LUC and tub-LUC, as well as growth inhibition in MBA-MB-231 cancer cells. eIF4A3-IN-15 is suitable for research applications focused on understanding the mechanisms underlying human cancer pathogenesis. -
eIF4F Inhibitor
eIF4A3-IN-9 is a potent eIF4F inhibitor that disrupts the formation of the eIF4F translation complex. Demonstrating EC50 values of 29 nM for myc-LUC, 450 nM for tub-LUC, and an effective growth inhibition in MBA-MB-231 cells, this compound serves as a valuable tool in the study of cancer biology. Its targeted action makes it suitable for investigating human cancer pathogenesis and exploring therapeutic strategies against malignancies. -
eIF Inhibitor
eIF4A3-IN-4 is a selective inhibitor of the eIF4A protein, exhibiting an IC50 value of 8.6 μM. This compound is relevant for research applications targeting the regulation of translation initiation and the modulation of gene expression. It has potential utility in studying cancer biology and other disorders related to abnormal protein synthesis. -
eIF4F Inhibitor
eIF4A3-IN-10 is an inhibitor of the eIF4F translation complex. It exhibits significant biological activity, with EC50 values of 35 nM for myc-LUC and 100 nM for growth inhibition in MBA-MB-231 cancer cells. This compound serves as a valuable tool in researching the pathogenesis of human cancers, particularly in the context of disrupted translation regulation associated with tumorigenesis. -
eIF4F Inhibitor
eIF4A3-IN-17 is an eIF4F inhibitor that disrupts the assembly of the eIF4F translation complex. It has demonstrated potent biological activity with EC50 values of 0.9 nM for myc-LUC, 15 nM for tub-LUC, and 1.8 nM for inhibiting the growth of MBA-MB-231 cells. This compound can be utilized in research focused on understanding human cancer pathogenesis and the mechanisms underlying oncogenic translation regulation. -
eIF4F Inhibitor
eIF4A3-IN-13 is an inhibitor of the eIF4F translation complex, functioning through disruption of its assembly. This compound exhibits potent biological activity, with EC50 values of 0.6 nM for myc-LUC, 15 nM for tub-LUC, and 0.4 nM for growth inhibition in MBA-MB-231 breast cancer cells. eIF4A3-IN-13 is a valuable tool for investigating the mechanisms of human cancer pathogenesis and exploring therapeutic strategies targeting translation regulation. -
eIF4F Inhibitor
eIF4A3-IN-11 is a potent inhibitor of the eIF4F translation complex. It effectively disrupts complex assembly, exhibiting EC50 values of 0.2 nM for myc-Luciferase, 4 nM for tubulin-Luciferase, and 0.3 nM for the inhibition of MBA-MB-231 cancer cell growth. This compound is valuable for investigating the molecular mechanisms underlying human cancer pathogenesis. -
eIF4A Inhibitor
eIF4A3-IN-14 is a selective inhibitor of eIF4A, a crucial component of the eIF4F translation complex. This compound demonstrates potent inhibitory activity with an EC50 of approximately 40 nM against myc-LUC and over 2000 nM against tub-LUC. eIF4A3-IN-14 is valuable for investigating tumorigenesis and the molecular mechanisms of translational regulation in cancer research. -
eIF Inhibitor
CMLD012612 is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), designed to disrupt the translation initiation process in eukaryotic cells. This amidino-rocaglate compound features a hydroxamate group, demonstrating significant cytotoxicity in NIH/3T3 cells, with an IC50 value of 2 nM. By modifying the activity of the RNA helicase eIF4A, CMLD012612 exhibits promising anti-neoplastic properties, making it a valuable tool for cancer research and studies focused on translation regulation. -
eIF Inhibitor
CMLD012073 is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), functioning through the mechanism of amidino-rocaglates. This compound effectively inhibits cell growth in NIH/3T3 cells with an IC50 value of 10 nM. CMLD012073 disrupts eukaryotic translation initiation by altering the activity of the RNA helicase eIF4A, making it a valuable tool for research applications related to protein synthesis and gene regulation. -
eIF Inhibitor
CMLD012072 is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), specifically targeting eIF4A1 and eIF4A2 through RNA clamping. This amidino-rocaglate compound exhibits significant anti-neoplastic activity, making it a valuable tool for researching the role of eIF4A in cancer biology and therapeutic interventions. Its mechanism of action provides insight into the regulation of protein synthesis in neoplastic cells, facilitating further studies in oncology and molecular biology. -
eIF4A3 Inhibitor
eIF4A3-IN-7 is a potent inhibitor of the eIF4A3 protein, a key regulator of mRNA translation and splicing. This compound demonstrates significant potential for research in cancer and other dysproliferative diseases by modulating gene expression pathways. Its targeted mechanism of action may provide valuable insights into the role of eIF4A3 in tumorigenesis and other pathological conditions. -
DNA Gyrase/Topoisomerase Inhibitor
Levofloxacin mesylate is a potent DNA gyrase and topoisomerase IV inhibitor. As an orally active antibiotic, it exhibits significant antibacterial activity against both Gram-positive and Gram-negative bacteria. This compound is applicable in various research contexts, including studies on chronic periodontitis, airway inflammation, and BK viremia. Additionally, levofloxacin mesylate demonstrates anti-orthopoxvirus properties, making it valuable for investigations into viral infections. -
Topoisomerase Inhibitor
OSUAB-0284 is a potent bacterial topoisomerase inhibitor, exhibiting significant anti-staphylococcal activity, particularly against methicillin-resistant Staphylococcus aureus (MRSA). By targeting and inhibiting bacterial topoisomerase, OSUAB-0284 effectively disrupts bacterial DNA replication and transcription processes. This compound is valuable for researching infections linked to drug-resistant bacteria, providing insights into potential therapeutic strategies against MRSA and other related pathogens. -
HSV Polymerases Inhibitor
PNU-183792 is a potent inhibitor of herpes simplex virus (HSV) polymerases, classified as a 4-oxo-dihydroquinoline. It demonstrates broad-spectrum antiviral activity, exhibiting IC50 values of 0.69 μM for human cytomegalovirus (HCM), 0.37 μM for varicella zoster virus, and 0.58 μM for HSV polymerases. Importantly, PNU-183792 operates selectively, showing no activity against human α, γ, or δ polymerases. Additionally, it exhibits inhibitory effects on simian varicella virus (SVV), murine cytomegalovirus (MCMV), and rat cytomegalovirus (RCMV), making it a valuable tool for antiviral research. -
Nucleoside Antimetabolite/Analog Inhibitor
Netivudine is a nucleoside antimetabolite that acts as an analog inhibitor with significant antiviral activity against varicella zoster virus. In addition to its biological applications, Netivudine features an alkyne group, enabling its use in click chemistry through copper-catalyzed azide-alkyne cycloaddition (CuAAc). This reagent is valuable for molecular biology research and chemical biology applications, particularly in the development of novel therapeutic agents. -
Topoisomerase II α/β Inhibitor
Chloroquinoxaline sulfonamide is a potent inhibitor of topoisomerase II α/β, disrupting the enzyme's function and causing DNA damage. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research. Additionally, it is employed in veterinary medicine to control coccidiosis in various livestock, including poultry, rabbits, sheep, and cattle. Its varied applications underscore its importance in both therapeutic and research settings. -
Ns5b Polymerase Inhibitor
Anti-infective agent 10 is an NS5B polymerase inhibitor designed for research into hepatitis C virus (HCV) infections. This compound effectively disrupts the viral replication process, making it a valuable tool for studying HCV biology and developing antiviral therapies. Its applications extend to evaluating drug resistance mechanisms and supporting drug discovery efforts in combating HCV. -
Ns5b Polymerase Inhibitor
HCV NS5B polymerase-IN-2 is an inhibitor targeting the NS5B polymerase of the hepatitis C virus (HCV). This compound demonstrates significant antiviral activity against HCV replication, making it a valuable tool for the investigation of hepatitis C viral infections and the development of therapeutic strategies. Its efficacy in inhibiting NS5B polymerase highlights its potential role in studying HCV dynamics and drug resistance. -
HCV/HDAC6 Inhibitor
Nicoxamat, also known as N-Hydroxynicotinamide, functions as an inhibitor of hepatitis C virus (HCV) and selectively targets HDAC6. This compound exhibits antiviral activity against HCV, making it a useful tool in research on hepatitis C infection. Its role as an HDAC6 inhibitor further supports investigations into epigenetic regulation and potential therapeutic strategies. -
HCV NS5B Polymerase Inhibitor
BI 207524 is a selective non-nucleoside inhibitor of HCV NS5B polymerase, specifically targeting thumb pocket 1. This compound demonstrates antiviral activity against hepatitis C virus (HCV). BI 207524 is applicable in research focused on HCV infection and the mechanisms of antiviral response. -
HCV Polymerase Inhibitor
HCVP-IN-1 is a potent inhibitor of hepatitis C viral polymerase (HCVP). This compound effectively disrupts viral replication, making it a valuable tool for studying the dynamics of hepatitis C virus infection. HCVP-IN-1 is particularly relevant in research focused on developing antiviral therapies and understanding the mechanisms of HCV-related diseases. -
DNA Methylation Inhibitor
Dihydro-5-azacytidine acetate is a nucleoside analog that functions as a DNA methylation inhibitor. It is incorporated into DNA, leading to the disruption of normal methylation patterns. This compound exhibits notable antitumor activity and is utilized in research focused on cancer biology and epigenetic regulation. -
PNP Inhibitor
BCX-5 is a selective inhibitor of purine nucleoside phosphorylase (PNP), offering an inhibitory potency with a Ki value of 0.08 μM. This compound is known to impede cell proliferation and modulate mixed lymphocyte reactions by elevating levels of inosine and guanosine in plasma. BCX-5 is valuable for research applications in immunology, providing insights into purine metabolism and lymphocyte function. -
DNA Methylation Inhibitor
Dihydro-5-azacytidine is a DNA methylation inhibitor that is incorporated into the DNA structure, disrupting normal methylation processes. This compound exhibits antitumor activity, making it a valuable tool for cancer research. Its properties are relevant for studies focused on epigenetic regulation and the development of therapeutic strategies targeting DNA methylation. -
Norovirus Inhibitor
CMX-521 is a nucleoside analog that functions as a potent inhibitor of the RNA-dependent RNA polymerase (RdRp) of norovirus. This compound effectively suppresses both murine norovirus (MNV) and human norovirus, making it a valuable tool for research into norovirus infections. Its inhibitory properties are essential for studies focused on antiviral development and mechanisms of norovirus replication. -
Thymidine Phosphorylase Inhibitor
5-Phenyluracil is a potent inhibitor of thymidine phosphorylase, an enzyme involved in nucleoside metabolism. This compound exhibits significant anti-tumor activity by disrupting the salvage pathway of nucleotides, making it relevant for cancer research. Its selective inhibition of thymidine phosphorylase highlights its potential utility in exploring cancer therapeutics and related biological pathways. -
Nucleoside Transport Inhibitor
Nitrobenzylthioinosine 5'-monophosphate (NBMPR-P) is a prodrug of the effective nucleoside transport inhibitor Nitrobenzylthioinosine (NBMPR). This compound primarily functions by blocking nucleoside transport in vivo, thereby mitigating host toxicity during high-dose Tubercidin treatment in tumor-bearing mice. NBMPR-P is valuable in research applications focusing on nucleoside transport mechanisms and related therapeutic interventions. -
Enzymes Inhibitor
5'-dUMPS is a competitive inhibitor of enzymes interacting with 2'-deoxypyrimidine-5'-monophosphate. It plays a crucial role in modulating nucleic acid synthesis and can be utilized in research focused on metabolic pathways and enzyme kinetics. Its capacity to regulate enzyme activity makes it a valuable tool for studies in molecular biology and pharmacology. -
Pain Inhibitor
Brivoligide (AYX1) is a double-stranded, unprotected oligonucleotide composed of 23 base pairs, functioning as a pain inhibitor. It has demonstrated efficacy in reducing acute post-surgical pain through its ability to mimic the DNA sequence typically bound by the transcription factor EGR1 on chromosomes. This unique mechanism makes Brivoligide a valuable tool for research applications focused on pain management and therapeutic interventions in pain-related conditions. -
MMP-2 Inhibitor
Homouridine is an uridine analogue that acts as an MMP-2 inhibitor, exhibiting an IC50 of 150 μM for compound I. This compound demonstrates significant biological activity through its ability to inhibit TNF-α binding to the TNF-αR1, making it valuable for research applications focused on inflammatory responses and extracellular matrix remodeling. Homouridine serves as a vital intermediate in the synthesis of MMP-2 inhibitors, facilitating studies in cancer and tissue repair mechanisms.
